An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan

In Taiwan, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), gefitinib, erlotinib, and afatinib are served as first-line therapy for non-small lung cell cancer (NSCLC) patients with EGFR sensitizing mutations. However, the majority of patients who initially respond to E...

Full description

Bibliographic Details
Main Authors: Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
afatinib
epidermal growth factor receptor mutation
erlotinib
gefitinib
non-small cell lung cancer
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01481/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01481/full

Similar Items